I need to know that the patients I schedule have a high probability of a successful outcome. I define “successful” as the patient says they benefit, and I earn a fee commensurate with my knowledge and experience.
Any glaucoma clinician knows that a robust VF strategy, coupled with structural measures, such as optical coherence tomography (OCT), provides a richer understanding of a patient’s disease than anatomical structure alone. Yet when it comes to age-related macular degeneration (AMD), I would argue that our diagnostic habits are quite different.